MoneyWorks4Me

Suven Life Sciences informs about press release

04 Jun 2026 Evaluate
Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Phase 3 Study of Masupirdine in Alzheimer's Disease Agitation at 50% study completers - Study to Continue Unchanged’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..